Moderna and Merck mRNA Cancer Vaccine Succeeds in Pivotal Phase 3 Melanoma Trial
In a major milestone for precision oncology, Moderna and Merck have announced that their co-developed personalized mRNA cancer vaccine (mRNA-4157/V940) achieved its primary endpoints in a pivotal Phase 3 clinical trial involving resected high-risk melanoma patients.
In a major milestone for precision oncology, Moderna and Merck have announced that their co-developed personalized mRNA cancer vaccine (mRNA-4157/V940) achieved its primary endpoints in a pivotal Phase 3 clinical trial involving resected high-risk melanoma patients The biotech & healthcare details above are what the Ars Technica report is actually claiming — not a full spec sheet.
Moderna and Merck mRNA Cancer Vaccine Succeeds in Pivotal Phase 3 Melanoma Trial. Confirm timing, pricing, and availability with Ars Technica before treating this as shipping news.
Tech Bytes is keeping a standalone URL for this biotech & healthcare story so it can be cited apart from the daily pulse. The claims in the lede are attributed to Ars Technica; numbers, dates, and product names should be checked there.
Get Tech Pulse Daily in Your Inbox
Join 45,000+ engineers, founders, and tech leaders receiving high-signal daily breakdowns directly from major publishers.
Zero spam. Unsubscribe anytime in one click.
When administered in combination with Merck anti-PD-1 therapy Keytruda, the personalized mRNA vaccine demonstrated a statistically significant 49% reduction in the risk of cancer recurrence or death compared to Keytruda monotherapy over a three-year monitoring window.
Each vaccine dose is custom-manufactured based on genetic sequencing of a patient individual tumor mutations, training the immune system to identify and destroy residual cancer cells. The companies plan to submit global regulatory filings by year-end.